On Target Laboratories
4065 Commercial Avenue
Northbrook
Illinois
60062-1851
United States
Tel: 855-478-2466
Fax: 847-664-7001
Website: http://www.ontargetlabs.com/
29 articles about On Target Laboratories
-
On Target Laboratories Names Scott Huennekens as Executive Chairperson of the Board
1/3/2024
On Target Laboratories, Inc. announced the appointment of Scott Huennekens as Executive Chairperson of the Board.
-
On Target Laboratories Granted New Technology Add-On Payment (NTAP) for CYTALUX® (pafolacianine) injection in Ovarian and Lung Cancer Indications
8/10/2023
On Target Laboratories, Inc. announced that the Centers for Medicare & Medicaid Services has granted a new technology add-on payment for CYTALUX for use in ovarian and lung cancer.
-
On Target Laboratories Announces Publication in Journal of Thoracic and Cardiovascular Surgery Phase 3 ELUCIDATE Trial of CYTALUX® (pafolacianine) Injection for Intraoperative Imaging of Lung Cancer
3/27/2023
On Target Laboratories, Inc., a privately held biotechnology company developing intraoperative molecular imaging (IMI) agents to target and illuminate cancer during surgery, today announced publication of results from the ELUCIDATE Phase 3 Trial of CYTALUX (pafolacianine) injection for use of IMI for cancer in the lung.
-
On Target Laboratories Announces Expanded Indication of CYTALUX® (pafolacianine) injection for Detection of Lung Cancer During Surgery
12/16/2022
On Target Laboratories, Inc. announced that the U.S. Food and Drug Administration has approved an expanded indication for the use of CYTALUX in lung cancer.
-
On Target Laboratories Announces Publication in Journal of Clinical Oncology of Results from Phase 3 Trial of CYTALUX® (pafolacianine) Injection for Intraoperative Imaging of Ovarian Cancer
9/12/2022
On Target Laboratories, Inc. today announced publication of results from the Phase 3 006 Study of CYTALUX (pafolacianine) injection for intraoperative imaging of folate receptor positive ovarian cancer in the peer-reviewed Journal of Clinical Oncology.
-
On Target Laboratories Completes ELUCIDATE Phase 3 Clinical Trial Investigating the Use of CYTALUX™ (pafolacianine) injection in Cancer in the Lung
1/13/2022
On Target Laboratories, Inc., today announced the completion of the Phase 3, randomized, multi-center, single dose, open-label ELUCIDATE (Enabling LUng Cancer IDentification Using FolATE Receptor Targeting) Trial, which investigated the use of CYTALUX (pafolacianine) injection in patients scheduled to undergo thoracic surgery for confirmed or suspected cancer in the lung.
-
The tool developed by On Target boosts the ability of surgeons to find and remove cancerous lesions during surgical procedures, increasing progression free and overall survival.
-
On Target Laboratories, Inc. Announces Results of Phase 3 Trial for Pafolacianine Sodium Injection for Intraoperative Illumination of Folate Receptor Positive Ovarian Cancer
5/20/2021
Results to be presented at the American Society of Clinical Oncology (ASCO) virtual scientific program on June 7
-
On Target Laboratories Secures $21 Million for Development and Commercialization of Pafolacianine Sodium Injection
3/24/2021
On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced they have secured $21 million in an expanded Series B funding round
-
On Target Laboratories Announces U.S. FDA Acceptance and Priority Review of New Drug Application for pafolacianine sodium injection for Identification of Ovarian Cancer During Surgery
3/3/2021
On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) for Priority review for pafolacianine sodium injection as an adjunct for identifying ovarian cancer during surgery.
-
On Target Laboratories Announces the Appointment of Tommy Lee as Vice President, Clinical Operations
12/3/2020
On Target Laboratories, Inc., a privately-held biotechnology company developing fluorescent markers to target and illuminate cancer during surgery, today announced that Tommy Lee, MSHS has joined the Company as Vice President, Clinical Operations.
-
Intraoperative Molecular Imaging of Non-Small Cell Lung Cancer Improves Outcomes for 26 Percent of Patients in Multi-Institutional Phase 2 Clinical Trial
1/27/2020
OTL38 Receives FDA Fast Track Designation for Lung Cancer as it Begins Phase 3 Clinical Trials
-
On Target Laboratories Appoints Vice President of Regulatory and Quality
10/18/2019
On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted imaging agents to improve cancer surgery, announced today the appointment of Kimberly Fabrizio as Vice President of Regulatory and Quality.
-
Positive Phase 2 Study Results Published for On Target's Intraoperative Cancer Imaging Agent
10/15/2019
Journal Reports OTL38 Reveals Undetected Cancer in 48% of Patients
-
On Target Completes OTL38 Phase 2 Clinical Trial in Lung Cancer
8/19/2019
On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted fluorescent imaging agents to improve cancer surgery, announced today that it has completed its Phase 2, multi-center, open-label clinical trial for OTL38 in the detection of lung cancer nodules in lung cancer patients during surgery.
-
BioSpace Movers & Shakers, Aug. 16
8/16/2019
Biopharma companies strengthen their executive ranks and boards with new additions. -
On Target Laboratories Announces Leadership Transition and Appoints Christopher Barys as Chief Executive Officer
8/12/2019
On Target Laboratories, Inc., a privately held biotechnology company that is developing tumor-targeted imaging agents to improve cancer surgery, today announced that Christopher Barys has joined the company as Chief Executive Officer and will join the board of directors.
-
On Target Laboratories Appoints Executive Vice President of Regulatory and Quality
3/26/2019
On Target Laboratories, Inc. announced the appointment of Donna Haire as Executive Vice President of Regulatory and Quality.
-
On Target Laboratories Announces Amendment to Ongoing Phase 3 Trial Expanding Camera System Compatibility
2/12/2019
On Target Laboratories, Inc. announced that the protocol for the company's Phase 3 clinical trial, OTL38 for Intra-operative Imaging of Folate Receptor Positive Ovarian Cancer, has been amended to allow the use of Quest Medical Imaging's Spectrum® Platform camera system.
-
On Target Laboratories Announces Publication Supporting Use of OTL78 to Highlight Prostate Cancer Lesions
10/15/2018
On Target Laboratories, Inc. announced today the publication of a study evaluating the effectiveness of On Target Laboratories' drug, OTL78, in highlighting malignant lesions during radical prostatectomies.